Thu, Jun 5, 2025
[Archive]
Volume 11, Issue 43 (Jun 2003)
J Adv Med Biomed Res 2003, 11(43): 31-36 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hashemipour S, Larijani B, Baradarjalili R, Mohajeri M. Effectiveness And Acting Period Of Sandostatin Lar In The Treatment Of Acromegaly. J Adv Med Biomed Res 2003; 11 (43) :31-36
URL: http://journal.zums.ac.ir/article-1-695-en.html
URL: http://journal.zums.ac.ir/article-1-695-en.html
Abstract: (149039 Views)
Background: Pharmacotherapy of acromegaly has been successful in recent years. The therapeutic efficacy of long-acting sandostatin in the treatment of acromegaly has been established in multiple studies. In this report, we investigated the effectiveness of multiple injections of sandostatin and its acting period in Tehran in 2001.
Materials and Methods: In this Quasi-experimental study five diagnosed patients with acromegaly after hypophysectomy were treated with sandostatin LAR and followed up for at least 63 days after injection. After octreotide test, a dose of 30 mg sandostatin was prescribed for 3 injections. Frequency of mean daily growth hormons (GH) less than 5µg/L were compared after the first and the third injections. Then acting time of the drug was assessed. The efficacy of 30 and 40 mg doses were compared in 3 cases.
Results: There was no relationship between response rate to octreotide and sandostatin. Frequency of GH<5µg/L after the third injection was higher than that of the first one (P<0.01). Therapeutic effect of the drug continued for 42 days after the treatment in responding patients.
Conclusion: Octreotide test (with single dose injection) is not a good method for prediction of patients' response to treatment. Measuring GH after multiple injections is a better method for this purpose. Drug injection interval should be determined separately for each patient.
Materials and Methods: In this Quasi-experimental study five diagnosed patients with acromegaly after hypophysectomy were treated with sandostatin LAR and followed up for at least 63 days after injection. After octreotide test, a dose of 30 mg sandostatin was prescribed for 3 injections. Frequency of mean daily growth hormons (GH) less than 5µg/L were compared after the first and the third injections. Then acting time of the drug was assessed. The efficacy of 30 and 40 mg doses were compared in 3 cases.
Results: There was no relationship between response rate to octreotide and sandostatin. Frequency of GH<5µg/L after the third injection was higher than that of the first one (P<0.01). Therapeutic effect of the drug continued for 42 days after the treatment in responding patients.
Conclusion: Octreotide test (with single dose injection) is not a good method for prediction of patients' response to treatment. Measuring GH after multiple injections is a better method for this purpose. Drug injection interval should be determined separately for each patient.
Type of Study: Original Research Article |
Received: 2008/11/30 | Accepted: 2003/06/15 | Published: 2003/06/15
Received: 2008/11/30 | Accepted: 2003/06/15 | Published: 2003/06/15
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
